Qualitek H1 FY27: consol PAT +38% YoY to ₹6.60 Cr, subsidiaries drag, margin dips QoQ
PAT +38.4% YoY · revenue +33.2% · margins expanding
₹72.27 Cr
+33.2% YoY
₹6.6 Cr
+38.4% YoY
9.03%
+0.3pp YoY
₹5.66
Qualitek Labs' consolidated PAT for H1 FY27 (half year ended 30 September 2026) rose 38.4% YoY to ₹6.60 Cr on revenue of ₹72.27 Cr, up 33.2% YoY — a print with PAT growth outrunning revenue, lifting net margin modestly to 9.13% from 8.79% a year ago. Standalone performance was considerably stronger: revenue up 54.2% YoY to ₹44.72 Cr and PAT up 77.1% YoY to ₹4.95 Cr, meaning the parent entity, not the subsidiaries, drove the consolidated beat. Interstellar Testing Centre, Quality & Testing Info Solutions and LabOps Global together contributed just ₹1.65 Cr to consolidated PAT, down 16.6% YoY from ₹1.97 Cr, on subsidiary revenue growth of only 9.2% YoY — a >35-percentage-point gap between standalone and consolidated profit growth that readers comparing the two statements should note explicitly.
Q2 FY-2027 vs prior quarters
Sequentially, the picture is softer: consolidated PAT fell 32.9% half-on-half from ₹9.83 Cr in H2 FY26, and net margin compressed nearly 486 bps from 13.99% to 9.13%, even as revenue edged up 2.8%. The squeeze sits on finance costs, which nearly doubled YoY to ₹3.87 Cr (from ₹1.92 Cr) as the company funded a sharp capex ramp — consolidated capital work-in-progress grew to ₹69.77 Cr from ₹45.28 Cr at March 2026 — largely on borrowed money (short-term borrowings up to ₹48.54 Cr from ₹32.85 Cr at March). There is no analyst coverage of Qualitek Labs (zero analysts tracked per screener data), so there is no street consensus to beat or miss, and the company has issued no formal guidance and no press release accompanying this result, so there is nothing on record to grade the print against.
The stock went into the print at ₹554, down 3.7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 5 quarters on our records; PAT has now risen for 2 consecutive quarters.
Corporate activity this half ties into the capex and margin story: the board approved a preferential allotment (₹20.02 Cr in equity) and convertible warrants to the promoter group (₹26.96 Cr) on 22 September 2026, explicitly earmarked for expanding existing laboratories and entering new territories/segments — shareholders cleared it at the 16 October EGM, and the company is now awaiting BSE in-principle approval. A subsidiary separately secured a work order from the Government of Meghalaya (19 October 2026), a new order-book addition, though it has not yet shown up in subsidiary profit growth. On governance, independent director Ajay Agarwal resigned on 29 October 2026, and a second EGM is called for 5 December 2026 to widen the MOA's objects clause to cover third-party inspection body and conformity-assessment activities — a scope expansion, not a financial event, but one that sets up where future growth could come from.
W1
Subsidiary profitability recovery — combined subsidiary PAT fell 16.6% YoY to ₹1.65 Cr in H1 FY27; watch whether it rebounds or slides further next half
W2
Finance cost and leverage trajectory — consolidated finance cost at ₹3.87 Cr (H1 FY27) vs ₹1.92 Cr a year ago on debt-funded CWIP; watch whether the pending ~₹47 Cr preferential+warrant raise reduces reliance on borrowings once BSE approval lands
W3
Outcome of the 5 Dec 2026 EGM on the MOA amendment enabling third-party inspection body/conformity-assessment activities, and any resulting revenue contribution in subsequent periods
SME-listed half-yearly filer (exempt from quarterly P&L under Reg 4 SME proviso): figures are 6-month cumulative Apr-Sep 2026, filed as the '2nd' half-yearly period per SEBI's integrated-filing circular, not a discrete 3-month quarter. No exceptional items in current or year-ago periods; figures converted from ₹ Lakh (÷100).